Callan Family Office LLC Acquires New Stake in Avantor, Inc. (NYSE:AVTR)

Callan Family Office LLC purchased a new stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 55,668 shares of the company's stock, valued at approximately $1,173,000.

Other institutional investors have also added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB increased its stake in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after buying an additional 625 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock valued at $34,000 after purchasing an additional 830 shares in the last quarter. Global Retirement Partners LLC increased its stake in shares of Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock valued at $52,000 after acquiring an additional 1,067 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after purchasing an additional 835 shares in the last quarter. Finally, UMB Bank n.a. boosted its holdings in Avantor by 56.3% in the fourth quarter. UMB Bank n.a. now owns 2,981 shares of the company's stock worth $63,000 after acquiring an additional 1,074 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP James Bramwell sold 3,758 shares of the company's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total transaction of $65,877.74. Following the sale, the executive vice president now directly owns 87,379 shares in the company, valued at $1,531,753.87. This represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Steven W. Eck sold 4,907 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total transaction of $86,019.71. Following the completion of the transaction, the chief accounting officer now owns 40,604 shares of the company's stock, valued at $711,788.12. This trade represents a 10.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

Remove Ads

Avantor Stock Performance

NYSE AVTR traded down $1.13 during trading hours on Wednesday, reaching $15.81. 10,885,416 shares of the company were exchanged, compared to its average volume of 6,618,075. Avantor, Inc. has a 1 year low of $15.37 and a 1 year high of $28.00. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. The business's 50 day simple moving average is $19.83 and its 200-day simple moving average is $22.21. The stock has a market capitalization of $10.76 billion, a P/E ratio of 15.20, a P/E/G ratio of 1.55 and a beta of 1.30.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the company posted $0.22 earnings per share. On average, equities research analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on AVTR shares. Morgan Stanley decreased their price objective on Avantor from $27.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Barclays decreased their price target on shares of Avantor from $26.00 to $23.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Wells Fargo & Company reduced their price objective on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Citigroup lowered their target price on shares of Avantor from $22.00 to $18.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Raymond James reissued an "outperform" rating and set a $24.00 price objective (down from $26.00) on shares of Avantor in a report on Monday, February 10th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.50.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.